Fig. 2: Pharmacologic activation of GPER inhibits leukemic cell survival via mitochondrial-related apoptosis. | Cell Death & Disease

Fig. 2: Pharmacologic activation of GPER inhibits leukemic cell survival via mitochondrial-related apoptosis.

From: Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia

Fig. 2

A CCK-8 assay of cell viability in the leukemic cells treated with corresponding concentrations of GPER agonist G-1 for 48 h, IC50 values were calculated on basis of drug concentrations that causes 50% cell viability. B Leukemic cells were treated with 1 μM G-1 for the corresponding times. C CCK-8 assay of cell viability in the primary blasts and PBMNCs from HD treated with G-1 for 48 h. D, E FCM of apoptosis in the cell lines treated with G-1 for 24 h, and western blotting of the indicated proteins. F Western blot analysis of Cyto C in the mitochondria fractions and cytosolic fraction of the cells treated with indicated drugs for 24 h. HSP60 or GAPDH were used as an internal control. G Western blot analysis of GPER in OCI-AML2 cells infected with two independent sh RNAs targeting GPER. H FCM of apoptosis in the cells treated with 1 μM G-1 for 24 h. The data are expressed as the mean ± SD (n = 3). *p < 0.05, **p < 0.01. ns, not significant.

Back to article page